Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2

Abstract

Background GMZ2 is a recombinant malaria vaccine inducing immune responses against Plasmodium falciparum (Pf) merozoite surface protein-3 and glutamate-rich protein. We used standardized controlled human malaria infection (CHMI) to assess the efficacy of this asexual blood-stage vaccine. Methods We vaccinated 50 healthy, adult volunteers with lifelong exposure to Pf 3 times, at 4-week intervals, with 30 or 100 µg GMZ2 formulated in CAF01, a liposome-based adjuvant; 100 µg GMZ2, formulated in Alhydrogel; or a control vaccine (Verorab). Approximately 13 weeks after the last vaccination, 35/50 volunteers underwent CHMI by direct venous inoculation of 3200 Pf sporozoites (Sanaria® PfSPZ Challenge). Results Adverse events were similarly distributed between GMZ2 and control vaccinees. Baseline-corrected anti-GMZ2 antibody concentrations 4 weeks after the last vaccination were higher in all 3 GMZ2-vaccinated arms, compared to the control group. All GMZ2 formulations induced similar antibody levels. CHMI resulted in 29/34 (85%) volunteers with Pf parasitemia and 15/34 (44%) with malaria (parasitemia and symptoms). The proportion of participants with malaria (2/5 control, 6/10 GMZ2-Alhydrogel, 2/8 30 µg GMZ2-CAF01, and 5/11 100 µg GMZ2-CAF01) and the time it took them to develop malaria were similar in all groups. Baseline, vaccine-specific antibody concentrations were associated with protection against malaria. Conclusions GMZ2 is well tolerated and immunogenic in lifelong–Pf-exposed adults from Gabon, with similar antibody responses regardless of formulation. CHMI showed no protective effect of prior vaccination with GMZ2, although baseline, vaccine-specific antibody concentrations were associated with protection. CHMI with the PfSPZ Challenge is a potent new tool to validate asexual, blood-stage malaria vaccines in Africa. Clinical Trials Registration Pan-African Clinical Trials: PACTR201503001038304

Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults

“…This substantially contributed to lower VE calculations in both arms of the study. Although 100% of nonimmune control subjects in the United States and Europe (73/73) 13,26,27,29,40,41 and Tanzania (34/34) 15,18 have been infected with this dose, in other settings in Africa, including Gabon (20/25), 27,42 Gambia (17/ 19), 28 and unpublished data from Mali (8/15) and Kenya (137/ 170) (submitted), this has not been the case.…”

Transcriptional and epigenetic characterization of early striosomes identifies Foxf2 and Olig2 as factors required for development of striatal compartmentation and neuronal phenotypic differentiation

“…of TFs that regulate the expression of genes involved in embryonic development as well as adult life. It is expressed in brain endothelial cells and is critical for elements of craniofacial development, including cochlear development 61,62 . In our transcriptomic analysis, Foxf2 is a hub gene ( Fig.…”

Case Studies: Challenge Studies in Low- and Middle-Income Countries

“…We identified 5 Sub-Saharan African HCS involving falciparum malaria in Tanzania, Kenya, and Gabon (Hodgson et al 2014;Shekalaghe et al 2014;Lell et al 2017;Dejon-Agobe et al 2018;Jongo et al 2018). These studies are part of an international research program using cryopreserved P. falciparum (Pf) sporozoites from a laboratory strain (NF54) known to be sensitive to chloroquine and produced in increasingly controlled laboratory settings since the 1980s (Chulay et al 1986).…”